Aurinia Pharmaceuticals (AUPH) 10-Q 2 Nov 23 2023 Q3 Quarterly report Financial data

COVER

COVER - shares	9 Months Ended
	Sep. 30, 2023	Nov. 01, 2023
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2023
Document Transition Report	false
Entity File Number	001-36421
Entity Registrant Name	Aurinia Pharmaceuticals Inc.
Entity Incorporation, State or Country Code	Z4
Entity Address, Address Line One	#140, 14315 - 118 Avenue
Entity Address, City or Town	Edmonton
Entity Address, State or Province	AB
Entity Address, Postal Zip Code	T5L 4S6
Entity Tax Identification Number	98-1231763
City Area Code	(250)
Local Phone Number	744-2487
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		143,608,164
Title of 12(b) Security	Common shares, no par value
Trading Symbol	AUPH
Security Exchange Name	NASDAQ
Amendment Flag	false
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q3
Entity Central Index Key	0001600620
Current Fiscal Year End Date	--12-31

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Current assets
Cash, cash equivalents and restricted cash	$ 46,397	$ 94,172
Short-term investments	291,503	295,218
Accounts receivable, net	37,946	13,483
Inventories, net	32,820	24,752
Prepaid expenses	16,158	13,580
Other current assets	1,645	1,334
Total current assets	426,469	442,539
Non-current assets
Long-term investments	591	0
Other non-current assets	1,518	13,339
Property and equipment, net	3,496	3,650
Acquired intellectual property and other intangible assets, net	5,261	6,425
Finance right-of-use asset, net	113,069	0
Operating right-of-use assets, net	4,609	4,907
Total assets	555,013	470,860
Current liabilities
Accounts payable and accrued liabilities	52,309	39,990
Deferred revenue	4,662	3,148
Other current liabilities	2,611	2,033
Finance lease liability	13,328	0
Operating lease liabilities	980	936
Total current liabilities	73,890	46,107
Non-current liabilities
Finance lease liability	72,193	0
Operating lease liabilities	6,713	7,152
Deferred compensation and other non-current liabilities	10,340	12,166
Total liabilities	163,136	65,425
Commitments and contingencies (Note 17)
SHAREHOLDER’S EQUITY
Common shares - no par value, unlimited shares authorized, 143,605 and 142,268 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively	1,198,560	1,185,309
Additional paid-in capital	109,711	85,489
Accumulated other comprehensive loss	(947)	(1,061)
Accumulated deficit	(915,447)	(864,302)
Total shareholders' equity	391,877	405,435
Total liabilities and shareholders' equity	$ 555,013	$ 470,860

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares shares in Thousands	Sep. 30, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Common stock, par value (in usd per share)	$ 0	$ 0
Common stock, issued (in shares)	143,605	142,268
Common stock, outstanding (in shares)	143,605	142,268

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Revenue
Total revenue, net	$ 54,515	$ 55,779	$ 130,418	$ 105,595
Operating expenses
Cost of sales	6,769	2,447	8,753	4,302
Selling, general and administrative	47,759	52,169	144,964	148,898
Research and development	13,605	10,973	39,413	35,118
Other (income) expense, net	2,645	(311)	(695)	647
Total cost of sales and operating expenses	70,778	65,278	192,435	188,965
Loss from operations	(16,263)	(9,499)	(62,017)	(83,370)
Interest expense	(1,400)	0	(1,465)	0
Interest income	4,514	1,464	12,429	2,209
Net loss before income taxes	(13,149)	(8,035)	(51,053)	(81,161)
Income tax expense	298	954	92	973
Net loss	(13,447)	(8,989)	(51,145)	(82,134)
Other comprehensive loss:
Unrealized gain (loss) on available-for-sale securities, net of tax of nil	73	326	114	(675)
Comprehensive loss	$ (13,374)	$ (8,663)	$ (51,031)	$ (82,809)
Basic loss per share (in usd per share)	$ (0.09)	$ (0.06)	$ (0.36)	$ (0.58)
Diluted loss per share (in usd per share)	$ (0.09)	$ (0.06)	$ (0.36)	$ (0.58)
Weighted-average common shares outstanding used in computation of basic loss per share (in shares)	142,847,000	141,856,000	143,085,000	141,831,000
Weighted-average common shares outstanding used in computation of diluted loss per share (in shares)	142,847,000	141,856,000	143,085,000	141,831,000
Product revenue, net
Revenue
Total revenue, net	$ 40,781	$ 25,502	$ 116,218	$ 75,142
License, royalty and collaboration revenue
Revenue
Total revenue, net	$ 13,734	$ 30,277	$ 14,200	$ 30,453

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Parenthetical) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Income Statement [Abstract]
Unrealized gain (loss) on available-for-sale securities, net of tax	$ 0	$ 0	$ 0	$ 0

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY - USD ($) shares in Thousands, $ in Thousands	Total	Common Shares	Additional paid in capital	Accumulated Other Comprehensive (Loss) Income	Accumulated Deficit
Balance (in shares) at Dec. 31, 2021		141,600
Balance at Dec. 31, 2021	$ 479,091	$ 1,177,051	$ 59,014	$ (852)	$ (756,122)
Increase (Decrease) in Stockholders' Equity
Shares issued on exercise of stock options and vesting of performance awards and restricted stock units (in shares)		383
Shares issued on exercise of stock options and vesting of restricted stock units	522	$ 5,064	(4,542)
Issuance of common shares in conjunction with ESPP program (in shares)		127
Issuance of common shares in conjunction with ESPP program	1,223	$ 1,905	(682)
Share-based compensation	25,398		25,398
Unrealized gain (loss) on available-for-sale securities, net	(675)			(675)
Net loss	(82,134)				(82,134)
Balance (in shares) at Sep. 30, 2022		142,110
Balance at Sep. 30, 2022	423,425	$ 1,184,020	79,188	(1,527)	(838,256)
Balance (in shares) at Jun. 30, 2022		141,892
Balance at Jun. 30, 2022	423,768	$ 1,180,884	74,004	(1,853)	(829,267)
Increase (Decrease) in Stockholders' Equity
Shares issued on exercise of stock options and vesting of performance awards and restricted stock units (in shares)		218
Shares issued on exercise of stock options and vesting of restricted stock units	0	$ 3,136	(3,136)
Share-based compensation	8,320		8,320
Unrealized gain (loss) on available-for-sale securities, net	326			326
Net loss	(8,989)				(8,989)
Balance (in shares) at Sep. 30, 2022		142,110
Balance at Sep. 30, 2022	$ 423,425	$ 1,184,020	79,188	(1,527)	(838,256)
Balance (in shares) at Dec. 31, 2022	142,268	142,268
Balance at Dec. 31, 2022	$ 405,435	$ 1,185,309	85,489	(1,061)	(864,302)
Increase (Decrease) in Stockholders' Equity
Shares issued on exercise of stock options and vesting of performance awards and restricted stock units (in shares)	558	1,127
Shares issued on exercise of stock options and vesting of restricted stock units	$ 3,024	$ 11,141	(8,117)
Issuance of common shares in conjunction with ESPP program (in shares)		210
Issuance of common shares in conjunction with ESPP program	906	$ 2,110	(1,204)
Share-based compensation	33,543		33,543
Unrealized gain (loss) on available-for-sale securities, net	114			114
Net loss	$ (51,145)				(51,145)
Balance (in shares) at Sep. 30, 2023	143,605	143,605
Balance at Sep. 30, 2023	$ 391,877	$ 1,198,560	109,711	(947)	(915,447)
Balance (in shares) at Jun. 30, 2023		143,369
Balance at Jun. 30, 2023	392,292	$ 1,196,480	98,832	(1,020)	(902,000)
Increase (Decrease) in Stockholders' Equity
Shares issued on exercise of stock options and vesting of performance awards and restricted stock units (in shares)		236
Shares issued on exercise of stock options and vesting of restricted stock units	1,151	$ 2,080	(929)
Share-based compensation	11,808		11,808
Unrealized gain (loss) on available-for-sale securities, net	73			73
Net loss	$ (13,447)				(13,447)
Balance (in shares) at Sep. 30, 2023	143,605	143,605
Balance at Sep. 30, 2023	$ 391,877	$ 1,198,560	$ 109,711	$ (947)	$ (915,447)

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Cash flows used in operating activities:
Net loss	$ (51,145)	$ (82,134)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization	6,698	2,487
Net amortization of premiums and discounts on short-term investments	(8,836)	(14)
Share-based compensation expense	33,543	25,398
Write-down of inventory	916	2,464
Other, net	(3,910)	601
Net changes in operating assets and liabilities
Accounts receivable, net	(24,463)	(26,356)
Inventories, net	(8,984)	(8,458)
Prepaid expenses and other current assets	(2,889)	(3,461)
Non-current operating assets	(16)	(830)
Accounts payable, accrued and other liabilities	11,812	875
Operating lease liabilities	(499)	(551)
Net cash used in operating activities	(47,773)	(89,979)
Cash flows used in investing activities:
Purchase of investments	(379,213)	(403,184)
Proceeds from investments	391,287	346,109
Upfront lease payment	(11,864)	(381)
Purchase of long-lived assets	(419)	(158)
Capitalized patent costs	(240)	0
Net cash provided by (used in) investing activities	(449)	(57,614)
Cash flows from financing activities
Proceeds from exercise of stock options and employee share purchase plan	3,929	1,745
Finance lease payment	(3,482)	0
Cash provided by financing activities	447	1,745
Net decrease in cash, cash equivalents and restricted cash	(47,775)	(145,848)
Cash, cash equivalents and restricted cash, beginning of period	94,172	231,900
Cash, cash equivalents and restricted cash, end of period	46,397	86,052
Supplemental cash flow information
Cash received for interest	3,559	1,705
Cash paid for income taxes	(339)	(779)
Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheets
Cash, cash equivalents	45,557	85,341
Restricted cash	840	711
Total cash, cash equivalents and restricted cash	$ 46,397	$ 86,052

Organization and Description of

Organization and Description of Business	9 Months Ended
	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Description of Business	Organization and Description of Business Aurinia Pharmaceuticals Inc. (Aurinia or the Company) is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations with a high unmet medical need that are impacted by autoimmune, kidney and rare diseases. In January 2021, the Company introduced LUPKYNIS ® (voclosporin), the first U.S. Food and Drug Administration (FDA) approved oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct pre-clinical, clinical, and regulatory activities to support the voclosporin development program as well as other assets. Aurinia engaged with Otsuka Pharmaceutical Co., Ltd. (Otsuka) as a collaboration partner for development and commercialization of LUPKYNIS in the European Union (EU), Japan, as well as the United Kingdom, Russia, Switzerland, Norway, Belarus, Iceland, Liechtenstein and Ukraine (collectively, the Otsuka Territories). On August 17, 2021, the Company announced the addition of two novel assets AUR200 and AUR300. AUR200 and AUR300 are currently undergoing pre-clinical development with projected submission to the FDA (or their equivalent) for AUR200 in 2023 and for AUR300 in 2024. On September 15, 2022, the European Commission (EC) granted marketing authorization of LUPKYNIS to Otsuka. The centralized marketing authorization is valid in all EU member states as well as in Iceland, Liechtenstein, Norway and Northern Ireland. As of April 1, 2023, Aurinia's head office and registered office is located at #140, 14315-118 Avenue, Edmonton, Alberta, Canada T5L 4S6. Aurinia also has a U.S. commercial office located at 77 Upper Rock Circle Suite 700, Rockville, Maryland, 20850 United States. Aurinia is incorporated pursuant to the Business Corporations Act (Alberta). The Company’s common shares are traded on the Nasdaq Global Market (Nasdaq) under the symbol AUPH.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments considered necessary for fair presentation in accordance with U.S. GAAP. The condensed consolidated balance sheet as of September 30, 2023 was derived from audited annual consolidated financial statements but does not include all annual disclosures required by U.S. GAAP. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2022. The results of operations for the three and nine months ended September 30, 2023 are not necessarily indicative of the results to be expected for the full year or any other future periods. These unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Aurinia Pharma U.S., Inc. (Delaware incorporated) and Aurinia Pharma Limited (UK incorporated). All intercompany balances and transactions have been eliminated in consolidation and operate in one segment. These unaudited condensed consolidated financial statements are presented in U.S. dollars, which is the Company's and all of its foreign subsidiaries' functional currency. Therefore, there is no currency translation adjustment upon consolidation as the remeasurement of gains or losses are recorded in the condensed consolidated statements of operations. All monetary assets and liabilities denominated in a foreign currency are remeasured into U.S. dollars at the exchange rate on the balance sheet date. Non-monetary assets and liabilities (along with their related expenses) are translated at the rate of exchange in effect on the date assets were acquired. Monetary income and expense items are translated at the average foreign currency period. Foreign exchange gains and losses arising on translation or settlement of a foreign currency denominated monetary item are included in the consolidated statements of operations and recorded in other (income) expense, net. Major Customers: The Company currently has two main customers for U.S. commercial sales of LUPKYNIS and a collaboration partnership with Otsuka for sales of semi-finished product and license, royalty, and collaboration revenue in the Otsuka Territories. The percentage of total revenues, net from our main customers were as follows: Three months ended Nine months ended 2023 2022 2023 2022 Product revenue, net 77% 48% 90% 74% License, royalty and collaboration revenue 21% 52% 9% 26% In late March 2022, the Company provided a nominal additional discount to both of its two main U.S. customers, applicable for the 2022 calendar year, in connection with holding additional amounts of LUPKYNIS on hand due to supply chain concerns. In December 2022, the Company extended the nominal discount to the end of 2023. Such discounts, or any future discounts, may result in reduced sales to these customers in subsequent periods and substantial fluctuations in revenues from period to period. The Company monitors economic conditions, the creditworthiness of customers and government regulations and funding, both domestically and abroad. The Company regularly communicates with its customers regarding the status of receivable balances. Global economic conditions and customer specific factors may require the Company to periodically reevaluate the collectability of its receivables and based on this evaluation the Company could potentially incur credit losses. The Company has had no historical write-offs related to customers or receivables. Significant Accounting Policies The Company's significant accounting policies have not changed from those previously described in the Company's Annual Report on Form 10-K for the year ended December 31, 2022. Product Revenues In the United States (and territories), the Company sells LUPKYNIS primarily to specialty pharmacies and specialty distributors. These customers subsequently distribute the Company's products to patients and healthcare providers. Revenues from product sales are recognized when the customer obtains control of the Company's product, which typically occurs upon delivery to the customer. Reserves for discounts and allowances: Product sales are recorded at the net sales price, which includes estimates of variable consideration for which reserves are established. These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the customer) or a liability (if the amount is payable to a party other than the customer). The Company's estimates of reserves established for variable consideration are calculated based upon utilizing the expected value method. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenues recognized will not occur in a future period. Amounts related to such items are estimated at contract inception and updated at the end of each reporting period as additional information becomes available. Significant judgment is required in estimating variable consideration. In making these estimates, the Company considers historical data, including patient mix and inventory sold to customers that has not yet been dispensed. The Company uses a data aggregator and historical claims to estimate variable consideration for inventory sold to customers, including specialty pharmacies and specialty distributors, that has not yet been dispensed. Actual amounts may ultimately differ from the Company's estimates. If actual results vary, the Company adjusts these estimates, which could have an effect on earnings in the period of adjustment. As of September 30, 2023, the Company did not have any material adjustments to variable consideration estimates based on actual results. These specific adjustments are detailed further in the Company's Annual Report on Form 10-K for the year ended December 31, 2022. Accounts Receivable, Net: Accounts receivable are stated at their net realizable value. The Company's accounts receivable primarily represent amounts due to the Company from product sales and from its Otsuka collaboration agreement (Note 12). As of September 30, 2023 and December 31, 2022, accounts receivable, net are $37.9 million and $13.5 million, respectively. The Company's standard credit terms range from 30 to 45 days and does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between the transfer of the promised good to the customer and receipt of payment will be one year or less. The Company estimates the allowance for doubtful accounts using the current expected credit loss, or CECL, model. Under the CECL model, the allowance for doubtful accounts reflects the net amount expected to be collected from the account receivables. Aurinia evaluates the collectability of these cash flows based on the asset’s amortized cost, the risk of loss even when that risk is remote, losses over an asset’s contractual life, and other relevant information available to the Company. Accounts receivable balances are written off against the allowance when it is probable that the receivable will not be collected. The allowance for doubtful accounts was nil as of September 30, 2023 and December 31, 2022. Share-Based Compensation: The Company follows ASC Topic 718, Compensation - Stock Compensation (ASC 718), which requires the measurement and recognition of compensation expense, based on estimated fair values, for all share-based awards made to employees and directors. The Company records compensation expense based on the fair value on the grant date using the graded accelerated vesting method for all share-based payments related to stock options, performance awards (PAs), restricted stock units (RSUs) and purchases under the Company's 2021 Employee Share Purchase Plan (ESPP). The estimated fair value of performance-based awards is measured on the grant date and is recognized when it is determined that it is probable that the performance condition will be achieved. The Company has elected a policy for all share-based awards to estimate forfeitures based on historical forfeiture experience at the time of grant and revise in subsequent periods if actual forfeitures differ from those estimates. Recently Adopted Accounting Pronouncements In November 2021, the FASB issued ASU No. 2021-10, Government Assistance (Topic 832) : Disclosures by Business Entities about Government Assistance, which requires business entities to make annual disclosures about transactions with a government (including government assistance) by analogizing to a grant or contribution accounting model. The required disclosures include the nature of the transaction, the entity's related accounting policy, the financial statement line items affected and the amounts reflected in the current period financial statements, as well as any significant terms and conditions. The guidance is effective for financial statements issued for annual periods beginning after December 15, 2021. The Company adopted the ASU effective January 1, 2022, with no material impact on the condensed consolidated financial statements as of September 30, 2023.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2023
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements The Company's financial instruments consist primarily of cash and cash equivalents, investments, accounts receivable, accounts payable and accrued liabilities. The carrying value of accounts receivable, accounts payable and accrued liabilities approximate their fair value because of their short-term nature. Estimated fair value of available-for-sale debt securities are generally based on prices obtained from commercial pricing services. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from sources independent from the Company) and to minimize the use of unobservable inputs (the Company’s assumptions about how market participants would price assets and liabilities). As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows: • Level 1 - Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. • Level 2 - Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. • Level 3 - Unobservable inputs that reflect the reporting entity’s own assumptions. The following table summarizes the financial assets (cash, cash equivalents, restricted cash and investments) measured at fair value on a recurring basis: September 30, 2023 (in thousands) Level 1 Level 2 Level 3 Total Financial assets: Cash, cash equivalents and restricted cash $ 46,397 $ — $ — $ 46,397 Corporate bonds — 32,396 — 32,396 Commercial paper — 93,916 — 93,916 Treasury bills — 80,213 — 80,213 Treasury bonds — 85,569 — 85,569 Yankee bonds — — — — Total financial assets $ 46,397 $ 292,094 $ — $ 338,491 December 31, 2022 (in thousands) Level 1 Level 2 Level 3 Total Financial assets: Cash, cash equivalents and restricted cash $ 94,172 $ — $ — $ 94,172 U.S. agency securities — 4,948 — 4,948 Corporate bonds — 104,080 — 104,080 Commercial paper — 125,187 — 125,187 Treasury bills — 12,282 — 12,282 Treasury bonds — 42,220 — 42,220 Yankee bonds — 6,501 — 6,501 Total financial assets $ 94,172 $ 295,218 $ — $ 389,390 The Company's Level 1 instruments include cash, cash equivalents and restricted cash that are valued using quoted market prices. Aurinia estimates the fair values of investments in corporate debt securities, government and government related securities and certificates of deposits by taking into consideration valuations obtained from third-party pricing services. The fair value of the Company's investments classified within Level 2 is based upon observable inputs that may include benchmark yield curves, reported trades, issuer spreads, benchmark securities and reference data including market research publications. At September 30, 2023 and December 31, 2022, the weighted average remaining contractual maturities of Aurinia's Level 2 investments were approximately 7 months. It is the Company's intent for these investments to have an overall rating of A-1, or higher, by Moody’s, Standard & Poor’s and Fitch. No credit loss allowance was recorded as of September 30, 2023 and December 31, 2022, as the Company does not believe the unrealized loss is a result of a credit loss due to the nature of the investments. Aurinia also considered the current and expected future economic and market conditions and determined that the estimate of credit losses was not significantly impacted. Refer to Note 4, “Cash, Cash Equivalents, Restricted Cash and Investments,” for the carrying amount and related unrealized gains (losses) by type of investment.

Cash, Cash Equivalents, Restric

Cash, Cash Equivalents, Restricted Cash and Investments	9 Months Ended
	Sep. 30, 2023
Investments, Debt and Equity Securities [Abstract]
Cash, Cash Equivalents, Restricted Cash and Investments	Cash, Cash Equivalents, Restricted Cash and Investments As of September 30, 2023 and December 31, 2022, the Company had $338.5 million and $389.4 million, respectively of cash, cash equivalents, restricted cash and investments summarized below. As of September 30, 2023 and December 31, 2022, $292.1 million and $295.2 million were available-for-sale debt securities which are carried at fair market value. September 30, 2023 (in thousands) Amortized Cost Unrealized Gains Unrealized Losses Estimated Fair Value Cash, cash equivalents and restricted cash $ 46,397 $ — $ — $ 46,397 Corporate bonds 31,820 — (15) 31,805 Commercial paper 93,960 — (44) 93,916 Treasury bills 80,210 3 — 80,213 Treasury bonds 85,654 — (85) 85,569 Yankee bonds — — — — Total cash, cash equivalents, restricted cash and short-term investments $ 338,041 $ 3 $ (144) $ 337,900 Total long-term investment corporate bond 592 — (1) 591 Total cash, cash equivalents, restricted cash and investments $ 338,491 December 31, 2022 (in thousands) Amortized Cost Unrealized Gains Unrealized Losses Estimated Fair Value Cash, cash equivalents and restricted cash $ 94,172 $ — $ — $ 94,172 U.S. agency securities 4,951 — (3) 4,948 Corporate bonds 104,174 — (94) 104,080 Commercial paper 125,255 — (68) 125,187 Treasury bills 12,290 — (8) 12,282 Treasury bonds 42,301 — (81) 42,220 Yankee bonds 6,503 — (2) 6,501 Total cash, cash equivalents, restricted cash and short-term investments $ 389,646 $ — $ (256) $ 389,390 As of September 30, 2023 and December 31, 2022, accrued interest receivable from investments were $0.7 million and $1.1 million, respectively. During the three and nine months ended September 30, 2023, the Company had $73 thousand and $114 thousand unrealized gains on available-for-sale securities, net of tax, respectively, which are included as a component of comprehensive loss on the consolidated statements of operations. During the three and nine months ended September 30, 2022, the Company had $0.3 million and $0.7 million unrealized gains and losses on available-for-sale securities, net of tax, respectively, which are included as a component of comprehensive loss on the consolidated statements of operations. Currently, the Company does not intend to sell investments that are in an unrealized loss position, and it is unlikely the Company will be required to sell the investments before recovery of their amortized cost basis, which may be at maturity. The Company has determined that the gross unrealized losses on investments at September 30, 2023, were temporary in nature. Realized gains or losses were immaterial during the three and nine months ended September 30, 2023 and 2022.

Inventories, net

Inventories, net	9 Months Ended
	Sep. 30, 2023
Inventory Disclosure [Abstract]
Inventories, net	Inventories, netInventories are valued under a standard costing methodology on a first-in, first-out basis and are stated at the lower of cost or net realizable value. The Company capitalizes inventory costs related to products to be sold in the ordinary course of business. The Company makes a determination of capitalizing inventory costs for a product based on, among other factors, status of regulatory approval, information regarding safety, efficacy and expectations relating to commercial sales and recoverability of costs. Capitalized costs of inventories for LUPKYNIS mainly include third party manufacturing costs, transportation, storage, insurance, and allocated internal labor. Due to the nature of the Company's supply chain process, inventory that is owned by the Company, is physically stored at third-party warehouses, logistics providers, and contract manufacturers. The Company assesses recoverability of inventory each reporting period to determine any write-down to net realizable value resulting from excess or obsolete inventories. As of September 30, 2023 and December 31, 2022, Aurinia recorded reserves of finished goods inventories of approximately $1.1 million and $3.9 million, respectively, which were primarily related to potential inventory obsolescence. The components of inventory, net are as follows: (in thousands) September 30, 2023 December 31, 2022 Raw materials $ 1,985 $ 2,217 Work in process 29,639 21,059 Finished goods, net of reserve 1,196 1,476 Total inventories, net $ 32,820 $ 24,752

Prepaid Expenses

Prepaid Expenses	9 Months Ended
	Sep. 30, 2023
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid Expenses	Prepaid Expenses Prepaid expenses are as follows: (in thousands) September 30, 2023 December 31, 2022 Prepaid assets $ 7,288 $ 5,451 Prepaid deposits 6,922 6,330 Prepaid insurance 1,948 1,799 Total prepaid expenses $ 16,158 $ 13,580

Intangible Assets

Intangible Assets	9 Months Ended
	Sep. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	Intangible Assets The following table summarizes the carrying amount of intangible assets, net of accumulated amortization. September 30, 2023 (in thousands) Gross Carrying Accumulated Net Carrying Patents $ 1,802 $ (1,287) $ 515 Acquired intellectual property and reacquired rights 15,126 (10,538) 4,588 Internal-use software implementation costs 2,873 (2,715) 158 $ 19,801 $ (14,540) $ 5,261 December 31, 2022 (in thousands) Gross Carrying Accumulated Net Carrying Patents $ 1,569 $ (1,262) $ 307 Acquired intellectual property and reacquired rights 15,126 (9,838) 5,288 Internal-use software implementation costs 2,873 (2,043) 830 $ 19,568 $ (13,143) $ 6,425

Property and Equipment, net

Property and Equipment, net	9 Months Ended
	Sep. 30, 2023
Property, Plant and Equipment [Abstract]
Property and Equipment, net	Property and Equipment, net Property and equipment, net are as follows: (in thousands) September 30, 2023 December 31, 2022 Construction in progress $ — $ 255 Leasehold improvements 3,243 2,978 Office equipment 631 645 Furniture 1,141 976 Computer equipment 235 251 5,250 5,105 Less accumulated depreciation (1,754) (1,455) Property and equipment, net $ 3,496 $ 3,650

Lease Obligations

Lease Obligations	9 Months Ended
	Sep. 30, 2023
Leases [Abstract]
Lease Obligations	Lease Obligations The Company has the following lease obligations: Victoria, British Columbia In December 2020, Aurinia entered into a lease for office space in Victoria, British Columbia. During September 2022, the fixed lease term ended on the Victoria lease and the Company exercised its right to enter into a short-term month to month lease, of which expenses are incurred in SG&A. On March 31, 2023, the Company terminated the Victoria lease. Rockville, Maryland During March 2020, the Company entered into a lease for its U.S. commercial office in Rockville, Maryland for a total of 30,531 square feet of office space. The lease has a remaining term of approximately eight years and has an option to extend for two five-year periods after the initial term of 11 years has elapsed and has an option to terminate after seven years. As of September 30, 2023, the Company had a right-of-use (ROU) asset of $4.6 million and lease liability of $7.5 million included in the condensed consolidated balance sheets. As of December 31, 2022, the Company had a right of use asset of $4.9 million and lease liability of $8.0 million included in the condensed consolidated balance sheets. The Company recorded leasehold improvement incentives in the amount of $2.3 million as additions to the lease liability. The lease term commenced on March 12, 2020. When measuring the lease liability, the Company discounted lease payments using its incremental borrowing rate at March 12, 2020. The incremental borrowing rate applied to the lease liability on March 12, 2020 was 5.2% based on the financial position of the Company, geographical region and term of lease. Edmonton, Alberta During October 2022, the Company entered into a long term lease in Edmonton for a total of 4,375 square feet of office space. The lease is a six year lease and has an option to renew after five years at prevailing market rates. The lease commenced on November 1, 2022 and the Company recorded the lease as an operating lease. The lease is not material to the Company's financial position. For all leases, the Company incurs variable lease costs. These costs include operation and maintenance costs included in SG&A and are expensed as incurred. The variable lease costs are not material to the Company's financial position. The operating lease costs for all leases for the three and nine months ended September 30, 2023 were $0.2 million and $0.6 million, respectively. Operating lease costs for the three and nine months ended September 30, 2022 were $0.2 million and $0.8 million, respectively. Monoplant On December 15, 2020, the Company entered into a collaborative agreement with Lonza to build a dedicated manufacturing facility within Lonza’s existing small molecule facility in Visp, Switzerland. The dedicated facility (also referred to as "monoplant") is equipped with state-of-the-art manufacturing equipment to provide cost and production efficiency for the manufacturing of voclosporin, while expanding existing capacity and providing supply security to meet future commercial demand. Following U.S. regulatory approval of LUPKYNIS in January 2021, the construction of the monoplant began. The Company has completed a capital expenditure payment program for the monoplant totaling approximately CHF 21.0 million. The first capital expenditure payment was made in February 2021 of $11.8 million (CHF 10.5 million) and was treated as an upfront lease payment and recorded under other non-current assets on the condensed consolidated balance sheets. The second payment of $11.9 million (CHF 10.5 million) became due when the facility fulfilled the required operational qualifications, which occurred during the second quarter of 2023. The Company now has the exclusive right to use the monoplant by paying a quarterly fixed facility fee. The Company has determined that the arrangement will be accounted for as a finance lease under ASC 842. Under ASC 842, the lease term begins at the commencement date and is based on the noncancellable period for which a lessee has the right to use an underlying asset. Aurinia determined that the lease commencement occurred at the point when the FDA manufacturing validation process began, which occurred during the three months ended June 30, 2023. The Company, at lease inception, recorded an ROU asset of approximately $117.6 million and a corresponding lease liability of $94.1 million, which is the present value of the minimum lease payments beginning July 2023 and expiring in 2030. The incremental borrowing rate applied to value the lease liability at inception is 6.19%, which was based on the financial position of the Company, geographical region and term of lease. As of September 30, 2023 the ROU asset, net and corresponding lease liability balance were $113.1 million and $85.5 million, respectively. For the three and nine months ended September 30, 2023, related to the lease, ROU amortization was $4.4 million and $4.6 million respectively, and interest expense was $1.4 million and $1.5 million, respectively. The following table represents the weighted-average remaining lease terms and discount rates as of September 30, 2023: As of September 30, 2023 Weighted Average Remaining Lease Term (years) Weighted Average Discount Rate Operating leases 7.9 5.28% Finance lease 6.5 6.19% Supplemental cash flow information related to the leases are as follows: Nine months ended 2023 2022 (in thousands) Cash paid for amounts included in the measurement of lease liabilities Financing cash flows from finance lease $ (3,482) $ — Operating cash flows from finance lease $ (718) $ — Operating cash flows from operating leases $ (805) $ (897) The following table provides a summary of lease liabilities payments for the next five years and thereafter: (in thousands) Finance Lease Payments Operating Lease Payments Remainder of 2023 $ 3,963 $ 276 2024 15,851 1,113 2025 15,851 1,141 2026 15,851 1,169 2027 15,851 1,198 Thereafter 35,663 4,533 Total future minimum lease payments 103,030 9,430 Less: lease imputed interest (17,509) (1,737) Total future minimum lease payments $ 85,521 $ 7,693 Beinheim

Accounts Payable and Accrued Li

Accounts Payable and Accrued Liabilities	9 Months Ended
	Sep. 30, 2023
Payables and Accruals [Abstract]
Accounts Payable and Accrued Liabilities	Accounts Payable and Accrued Liabilities Accounts payable and accrued liabilities are as follows: (in thousands) September 30, 2023 December 31, 2022 Employee accruals $ 18,177 $ 20,214 Commercial accruals 13,437 8,620 Accrued R&D projects 5,678 5,350 Trade payables 8,854 3,087 Other accrued liabilities 5,938 2,094 Income taxes payable 225 625 Total accounts payable and accrued liabilities $ 52,309 $ 39,990

Deferred Compensation and Other

Deferred Compensation and Other Non-current Liabilities	9 Months Ended
	Sep. 30, 2023
Payables and Accruals [Abstract]
Deferred Compensation and Other Non-current Liabilities	Deferred Compensation and Other Non-current LiabilitiesThe Company recorded other non-current liabilities of $10.3 million and $12.2 million as of September 30, 2023 and December 31, 2022, respectively. The balance as of September 30, 2023 and December 31, 2022 primarily included deferred compensation arrangements whereby certain former executive officers as of March 8, 2012 were provided with future potential employee benefit obligations for remaining with the Company for a certain period of time. These obligations are also contingent on the occurrence of uncertain future events.

License and Collaboration Agree

License and Collaboration Agreements	9 Months Ended
	Sep. 30, 2023
Revenue from Contract with Customer [Abstract]
License and Collaboration Agreements	License and Collaboration Agreements Otsuka Contract On December 17, 2020, the Company entered into a collaboration and license agreement with Otsuka for the development and commercialization of oral LUPKYNIS in the Otsuka Territories. As part of the agreement, the Company received an upfront cash payment of $50.0 million in 2020 for the license agreement and has the potential to receive up to $50.0 million in regulatory and pricing approval related milestones. The Company provides semi-finished product of LUPKYNIS to Otsuka on a cost-plus basis, and receives tiered royalties ranging from 10 to 20 percent (dependent on territory and achievement of sale thresholds) on net product sales by Otsuka, along with additional milestone payments based on the attainment of certain annual sales. In addition, certain collaboration services are to be provided to Otsuka on agreed upon rates. In furtherance of the collaboration and license agreement with Otsuka mentioned above, on August 1, 2022, the Company entered into a commercial supply agreement with Otsuka, formalizing the terms to supply semi-finished goods of LUPKYNIS to Otsuka in the Otsuka Territories, including sharing production capacity of the monoplant. On September 15, 2022, the European Commission (EC) granted marketing authorization of LUPKYNIS. The centralized marketing authorization is valid in all EU member states as well as in Iceland, Liechtenstein, Norway and Northern Ireland. The approval triggered a $30.0 million milestone to the Company, which was recognized as collaboration revenue for the year ended December 31, 2022. On November 29, 2022 Aurinia announced that the MHRA had granted marketing authorization of LUPKYNIS in Great Britain. On April 24, 2023, LUPKYNIS received regulatory approval in Switzerland. The Company continues to progress with regulatory approval with Otsuka in the other Otsuka Territories. During the three months ended September 30, 2023, the Company received notification that the pricing and reimbursement milestone was secured. As a result, this triggered a $10.0 million milestone which was recognized as collaboration revenue in the quarter . For the three and nine months ended September 30, 2023, the Company recognized $12.7 million and $13.2 million, respectively of license, royalty and collaboration revenue from services provided under the Otsuka agreement. For the three and nine months ended September 30, 2022, the Company recognized $30.2 million and $30.4 million, respectively. Riptide License On August 17, 2021, AUR300 (M2 macrophage modulation via CD206 binding) was secured through a global licensing and research agreement with Riptide Bioscience, Inc. (Riptide), a private company. As part of the agreement, in 2021 the Company paid Riptide an upfront license fee of $6.0 million which was expensed as research and development on the condensed consolidated statements of operations. During the first quarter of 2022, Aurinia paid $4.0 million for the achievement of a one-time milestone. Additional payments are due upon certain development, clinical and regulatory milestones, and royalties will be payable upon commercialization.

Net Loss per Common Share

Net Loss per Common Share	9 Months Ended
	Sep. 30, 2023
Earnings Per Share [Abstract]
Net Loss per Common Share	Net Loss per Common Share Basic and diluted net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding. Since the Company was in a loss position for all periods presented, diluted net loss per share is the same as basic net loss per share. The numerator and denominator used in the calculation of basic and diluted net loss per common share are as follows: Three months ended Nine months ended (in thousands, except per share data) 2023 2022 2023 2022 Net loss $ (13,447) $ (8,989) $ (51,145) $ (82,134) Weighted average common shares outstanding 142,847 141,856 143,085 141,831 Net loss per common share (expressed in $ per share) $ (0.09) $ (0.06) $ (0.36) $ (0.58) The Company did not include the securities in the following table in the computation of the net loss per common share because the effect would have been anti-dilutive during each period: Nine months ended (in thousands) 2023 2022 Stock options 12,400 14,299 Unvested performance awards 921 — Unvested restricted stock units 6,968 2,098 20,289 16,397

Share-based Compensation

Share-based Compensation	9 Months Ended
	Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]
Share-based Compensation	Share-based Compensation The Company's Amended and Restated Equity Incentive Plan (the Plan), which was adopted and approved by the Company's shareholders in June 2021, allows for an issuance of up to an aggregate of 23.8 million shares and provides for grants of stock options, performance awards (PAs), and restricted stock units (RSUs) that may be settled in cash and common shares. Also in June 2021, the Company's shareholders adopted and approved the Company's 2021 ESPP, which allows for the issuance of up to 2.5 million shares. The 2021 ESPP is intended to qualify as an “employee stock purchase plan” under Section 423 of the Internal Revenue Code but also permits the Company to include the employees, including non-United States employees, in offerings not intended to qualify under Section 423. The purpose of the 2021 ESPP is to provide eligible employees with opportunities to purchase the Company’s common shares at a discounted price. During 2022, the Company modified the 2021 ESPP for the current and future offerings. The new ESPP terms shortened the plan from four purchases over a 24-month offering period to two purchases over a 12-month offering period. Additionally, the ESPP now contains a rollover mechanism; that is, if the stock price on the purchase date is less than the offering price (as that is determined under the 2021 ESPP), that offering is then canceled and any participants are rolled into a new 12-month offering period at the lower price. In addition to stock options, PAs and RSUs granted under the Plan, the Company has granted certain stock options and RSUs as inducements material to new employees entering employment in accordance with Nasdaq Listing Rule 5635(c)(4). The inducements were granted outside of the Plan. Stock Options The Plan requires the exercise price of each option not to be less than the closing market price of the Company’s common shares on the business day immediately prior to the date of grant. The Board of Directors approves the vesting criteria and periods at its discretion. The options issued under the Plan are accounted for as equity-settled share-based payments. The Company used the Black-Scholes option pricing model to estimate the fair value of the options granted. The assumptions used for the annual volatility and expected life of the options are reviewed and updated annually. The Company considers historical volatility of its common shares in estimating its future stock price volatility. The risk-free interest rate for the expected life of the options was based on the yield available on government benchmark bonds with an approximate equivalent remaining term at the time of the grant. The expected life is based upon the contractual term, taking into account expected employee exercise and expected post-vesting employment termination behavior. The following weighted average assumptions were used to estimate the fair value of the options granted during the nine months ended September 30, 2023 and September 30, 2022: 2023 2022 Annualized volatility 71 % 70 % Risk-free interest rate 3.92 % 2.01 % Expected life of options in years 5.0 years 5.0 years Estimated forfeiture rate 12.7 % 12.1 % Dividend rate 0.0 % 0.0% Fair value per common share option $ 5.94 $ 6.60 The increase of the risk-free interest rate during the nine months ended September 30, 2023 was due to the increase of higher yields on government benchmark bonds. The following table summarizes the option award activity for the nine months ended September 30, 2023: September 30, 2023 Number of shares (in thousands) Weighted average exercise price $ Outstanding - December 31, 2022 13,295 $ 12.09 Granted 675 9.68 Exercised (558) 5.27 Forfeited (1,012) 14.11 Outstanding - September 30, 2023 12,400 $ 12.10 Restricted Stock Units and Performance Awards The Company has granted RSUs and PAs under the Plan, as well as inducements for certain new hires as discussed above. The RSUs and PAs are fair valued based on the previous business days' market price of common shares on the date of the grant. The following table summarizes the RSU and PA activity for the nine months ended September 30, 2023: September 30, 2023 Number of shares (in thousands) Weighted average fair value price $ Outstanding - December 31, 2022 1,980 $ 10.84 Granted 6,775 9.04 Vested (569) 11.71 Forfeited (297) 9.31 Outstanding - September 30, 2023 7,889 $ 9.29 Compensation Expense The Company recognized share-based compensation expense for the three and nine months ended September 30, 2023 and September 30, 2022 as follows: Three months ended Nine months ended (in thousands) 2023 2022 2023 2022 Research and development $ 1,975 $ 1,489 $ 5,679 $ 3,531 Selling, general and administrative 9,560 6,625 26,969 21,480 Capitalized under inventories 273 206 895 387 Share-based compensation expense $ 11,808 $ 8,320 $ 33,543 $ 25,398 As of September 30, 2023, there was $39.2 million of unrecognized share-based compensation expense related to unvested awards granted which is expected to be recognized over a weighted-average period of approximately 1.4 years.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2023
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The effective tax rates for the three and nine months ended September 30, 2023 and September 30, 2022 differed from the federal statutory rate applied to losses before income taxes primarily as a result of the mix of income, losses and valuation allowances. The Company recognized an income tax expense of approximately $298 thousand and $92 thousand for the three and nine months ended September 30, 2023 respectively. The Company recognized an income tax expense of approximately $954 thousand and $973 thousand for the three and nine months ended September 30, 2022. The 2023 quarter to date income tax expense recognized for 2023 relates to a current period tax expense that is not offset by a tax benefit as the Company had losses which were fully offset by a valuation allowance in its significant jurisdictions and withholding taxes on foreign income. The 2023 year to date tax expense is partially offset by a prior period favorable adjustment in U.S. income taxes. The income tax expense recognized for 2022 was a result of income in certain jurisdictions. The tax expense was not offset by a tax benefit as the Company had losses which were fully offset by a valuation allowance in its significant jurisdictions.

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2023
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions ILJIN is considered to be a related party due to their equity ownership of over 5%. The outstanding related party amount payable to ILJIN is the result of a milestone achieved as of September 30, 2023. The amount payable to ILJIN of $0.5 million as of September 30, 2023 was recorded in other current liabilities. On September 21, 2023, the Company appointed Dr. Robert T. Foster to the Board of Directors. Dr. Foster is considered a related party since he is one of the former executive officers of the Company who, as of March 8, 2012 was provided with future potential employee benefit obligations for remaining with the Company for a certain period of time. These obligations are contingent on the occurrence of uncertain future events. As of September 30, 2023, the Company had $0.5 million and $6.4 million of current and non-current liabilities related to Dr. Foster, respectively. From the time that Dr. Foster became a related party, the Company has not made any payments to him for the former employee benefit obligations.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies The Company may, from time to time, be subject to claims and legal proceedings brought against it in the normal course of business. Such matters are subject to many uncertainties. Management believes the ultimate resolution of such contingencies will not have a material adverse effect on the consolidated financial position of the Company. The Company's material commitments and contingencies have not changed in any material manner from those previously described in the Company's Annual Report on Form 10-K for the year ended December 31, 2022 and the quarterly report for the quarter ended June 30, 2023. Other Funding Commitments In the normal course of business, the Company enters into agreements with contract research organizations, contract manufacturing organizations and other third parties for services to be provided to the Company. Generally, these agreements

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Pay vs Performance Disclosure
Net loss	$ (13,447)	$ (8,989)	$ (51,145)	$ (82,134)

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments considered necessary for fair presentation in accordance with U.S. GAAP. The condensed consolidated balance sheet as of September 30, 2023 was derived from audited annual consolidated financial statements but does not include all annual disclosures required by U.S. GAAP. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2022. The results of operations for the three and nine months ended September 30, 2023 are not necessarily indicative of the results to be expected for the full year or any other future periods.
Major Customers	Major Customers: The Company currently has two main customers for U.S. commercial sales of LUPKYNIS and a collaboration partnership with Otsuka for sales of semi-finished product and license, royalty, and collaboration revenue in the Otsuka Territories. The percentage of total revenues, net from our main customers were as follows: Three months ended Nine months ended 2023 2022 2023 2022 Product revenue, net 77% 48% 90% 74% License, royalty and collaboration revenue 21% 52% 9% 26% In late March 2022, the Company provided a nominal additional discount to both of its two main U.S. customers, applicable for the 2022 calendar year, in connection with holding additional amounts of LUPKYNIS on hand due to supply chain concerns. In December 2022, the Company extended the nominal discount to the end of 2023. Such discounts, or any future discounts, may result in reduced sales to these customers in subsequent periods and substantial fluctuations in revenues from period to period. The Company monitors economic conditions, the creditworthiness of customers and government regulations and funding, both domestically and abroad. The Company regularly communicates with its customers regarding the status of receivable balances. Global economic conditions and customer specific factors may require the Company to periodically reevaluate the collectability of its receivables and based on this evaluation the Company could potentially incur credit losses. The Company has had no historical write-offs related to customers or receivables.
Product Revenues	Product Revenues In the United States (and territories), the Company sells LUPKYNIS primarily to specialty pharmacies and specialty distributors. These customers subsequently distribute the Company's products to patients and healthcare providers. Revenues from product sales are recognized when the customer obtains control of the Company's product, which typically occurs upon delivery to the customer. Reserves for discounts and allowances: Product sales are recorded at the net sales price, which includes estimates of variable consideration for which reserves are established. These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the customer) or a liability (if the amount is payable to a party other than the customer). The Company's estimates of reserves established for variable consideration are calculated based upon utilizing the expected value method. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenues recognized will not occur in a future period. Amounts related to such items are estimated at contract inception and updated at the end of each reporting period as additional information becomes available. Significant judgment is required in estimating variable consideration. In making these estimates, the Company considers historical data, including patient mix and inventory sold to customers that has not yet been dispensed. The Company uses a data aggregator and historical claims to estimate variable consideration for inventory sold to customers, including specialty pharmacies and specialty distributors, that has not yet been dispensed. Actual amounts may ultimately differ from the Company's estimates. If actual results vary, the Company adjusts these estimates, which could have an effect on earnings in the period of adjustment. As of September 30, 2023, the Company did not have any material adjustments to variable consideration
Accounts Receivable, Net	Accounts Receivable, Net: Accounts receivable are stated at their net realizable value. The Company's accounts receivable primarily represent amounts due to the Company from product sales and from its Otsuka collaboration agreement (Note 12). As of September 30, 2023 and December 31, 2022, accounts receivable, net are $37.9 million and $13.5 million, respectively. The Company's standard credit terms range from 30 to 45 days and does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between the transfer of the promised good to the customer and receipt of payment will be one year or less. The Company estimates the allowance for doubtful accounts using the current expected credit loss, or CECL, model. Under the CECL model, the allowance for doubtful accounts reflects the net amount expected to be collected from the account receivables. Aurinia evaluates the collectability of these cash flows based on the asset’s amortized cost, the risk of loss even when that risk is remote, losses over an asset’s contractual life, and other relevant information available to the Company. Accounts receivable balances are written off against the allowance when it is probable that the receivable will not be collected. The allowance for doubtful accounts was nil as of September 30, 2023 and December 31, 2022.
Share-Based Compensation	Share-Based Compensation: The Company follows ASC Topic 718, Compensation - Stock Compensation (ASC 718), which requires the measurement and recognition of compensation expense, based on estimated fair values, for all share-based awards made to employees and directors. The Company records compensation expense based on the fair value on the grant date using the graded accelerated vesting method for all share-based payments related to stock options, performance awards (PAs), restricted stock units (RSUs) and purchases under the Company's 2021 Employee Share Purchase Plan (ESPP). The estimated fair value of performance-based awards is measured on the grant date and is recognized when it is determined that it is probable that the performance condition will be achieved. The Company has elected a policy for all share-based awards to estimate forfeitures based on historical forfeiture experience at the time of grant and revise in subsequent periods if actual forfeitures differ from those estimates.
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements In November 2021, the FASB issued ASU No. 2021-10, Government Assistance (Topic 832) : Disclosures by Business Entities about Government Assistance, which requires business entities to make annual disclosures about transactions with a government (including government assistance) by analogizing to a grant or contribution accounting model. The required disclosures include the nature of the transaction, the entity's related accounting policy, the financial statement line items affected and the amounts reflected in the current period financial statements, as well as any significant terms and conditions. The guidance is effective for financial statements issued for annual periods beginning after December 15, 2021. The Company adopted the ASU effective January 1, 2022, with no material impact on the condensed consolidated financial statements as of September 30, 2023.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
Schedule of Total Revenues, Net From Main Customers	The percentage of total revenues, net from our main customers were as follows: Three months ended Nine months ended 2023 2022 2023 2022 Product revenue, net 77% 48% 90% 74% License, royalty and collaboration revenue 21% 52% 9% 26%

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2023
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The following table summarizes the financial assets (cash, cash equivalents, restricted cash and investments) measured at fair value on a recurring basis: September 30, 2023 (in thousands) Level 1 Level 2 Level 3 Total Financial assets: Cash, cash equivalents and restricted cash $ 46,397 $ — $ — $ 46,397 Corporate bonds — 32,396 — 32,396 Commercial paper — 93,916 — 93,916 Treasury bills — 80,213 — 80,213 Treasury bonds — 85,569 — 85,569 Yankee bonds — — — — Total financial assets $ 46,397 $ 292,094 $ — $ 338,491 December 31, 2022 (in thousands) Level 1 Level 2 Level 3 Total Financial assets: Cash, cash equivalents and restricted cash $ 94,172 $ — $ — $ 94,172 U.S. agency securities — 4,948 — 4,948 Corporate bonds — 104,080 — 104,080 Commercial paper — 125,187 — 125,187 Treasury bills — 12,282 — 12,282 Treasury bonds — 42,220 — 42,220 Yankee bonds — 6,501 — 6,501 Total financial assets $ 94,172 $ 295,218 $ — $ 389,390

Cash, Cash Equivalents, Restr_2

Cash, Cash Equivalents, Restricted Cash and Investments (Tables)	9 Months Ended
	Sep. 30, 2023
Investments, Debt and Equity Securities [Abstract]
Summary of Cash, Cash Equivalents, Restricted Cash and Investments	September 30, 2023 (in thousands) Amortized Cost Unrealized Gains Unrealized Losses Estimated Fair Value Cash, cash equivalents and restricted cash $ 46,397 $ — $ — $ 46,397 Corporate bonds 31,820 — (15) 31,805 Commercial paper 93,960 — (44) 93,916 Treasury bills 80,210 3 — 80,213 Treasury bonds 85,654 — (85) 85,569 Yankee bonds — — — — Total cash, cash equivalents, restricted cash and short-term investments $ 338,041 $ 3 $ (144) $ 337,900 Total long-term investment corporate bond 592 — (1) 591 Total cash, cash equivalents, restricted cash and investments $ 338,491 December 31, 2022 (in thousands) Amortized Cost Unrealized Gains Unrealized Losses Estimated Fair Value Cash, cash equivalents and restricted cash $ 94,172 $ — $ — $ 94,172 U.S. agency securities 4,951 — (3) 4,948 Corporate bonds 104,174 — (94) 104,080 Commercial paper 125,255 — (68) 125,187 Treasury bills 12,290 — (8) 12,282 Treasury bonds 42,301 — (81) 42,220 Yankee bonds 6,503 — (2) 6,501 Total cash, cash equivalents, restricted cash and short-term investments $ 389,646 $ — $ (256) $ 389,390

Inventories, net (Tables)

Inventories, net (Tables)	9 Months Ended
	Sep. 30, 2023
Inventory Disclosure [Abstract]
Schedule of Inventories, net	The components of inventory, net are as follows: (in thousands) September 30, 2023 December 31, 2022 Raw materials $ 1,985 $ 2,217 Work in process 29,639 21,059 Finished goods, net of reserve 1,196 1,476 Total inventories, net $ 32,820 $ 24,752

Prepaid Expenses (Tables)

Prepaid Expenses (Tables)	9 Months Ended
	Sep. 30, 2023
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Schedule of Prepaid Expenses and Other Current Assets	Prepaid expenses are as follows: (in thousands) September 30, 2023 December 31, 2022 Prepaid assets $ 7,288 $ 5,451 Prepaid deposits 6,922 6,330 Prepaid insurance 1,948 1,799 Total prepaid expenses $ 16,158 $ 13,580

Intangible Assets (Tables)

Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets	The following table summarizes the carrying amount of intangible assets, net of accumulated amortization. September 30, 2023 (in thousands) Gross Carrying Accumulated Net Carrying Patents $ 1,802 $ (1,287) $ 515 Acquired intellectual property and reacquired rights 15,126 (10,538) 4,588 Internal-use software implementation costs 2,873 (2,715) 158 $ 19,801 $ (14,540) $ 5,261 December 31, 2022 (in thousands) Gross Carrying Accumulated Net Carrying Patents $ 1,569 $ (1,262) $ 307 Acquired intellectual property and reacquired rights 15,126 (9,838) 5,288 Internal-use software implementation costs 2,873 (2,043) 830 $ 19,568 $ (13,143) $ 6,425

Property and Equipment, net (Ta

Property and Equipment, net (Tables)	9 Months Ended
	Sep. 30, 2023
Property, Plant and Equipment [Abstract]
Property and Equipment, net	Property and equipment, net are as follows: (in thousands) September 30, 2023 December 31, 2022 Construction in progress $ — $ 255 Leasehold improvements 3,243 2,978 Office equipment 631 645 Furniture 1,141 976 Computer equipment 235 251 5,250 5,105 Less accumulated depreciation (1,754) (1,455) Property and equipment, net $ 3,496 $ 3,650

Lease Obligations (Tables)

Lease Obligations (Tables)	9 Months Ended
	Sep. 30, 2023
Leases [Abstract]
Lease, Cost	The following table represents the weighted-average remaining lease terms and discount rates as of September 30, 2023: As of September 30, 2023 Weighted Average Remaining Lease Term (years) Weighted Average Discount Rate Operating leases 7.9 5.28% Finance lease 6.5 6.19% Supplemental cash flow information related to the leases are as follows: Nine months ended 2023 2022 (in thousands) Cash paid for amounts included in the measurement of lease liabilities Financing cash flows from finance lease $ (3,482) $ — Operating cash flows from finance lease $ (718) $ — Operating cash flows from operating leases $ (805) $ (897)
Lessee, Operating Lease, Liability, Maturity	The following table provides a summary of lease liabilities payments for the next five years and thereafter: (in thousands) Finance Lease Payments Operating Lease Payments Remainder of 2023 $ 3,963 $ 276 2024 15,851 1,113 2025 15,851 1,141 2026 15,851 1,169 2027 15,851 1,198 Thereafter 35,663 4,533 Total future minimum lease payments 103,030 9,430 Less: lease imputed interest (17,509) (1,737) Total future minimum lease payments $ 85,521 $ 7,693

Accounts Payable and Accrued _2

Accounts Payable and Accrued Liabilities (Tables)	9 Months Ended
	Sep. 30, 2023
Payables and Accruals [Abstract]
Schedule of Accrued Liabilities	Accounts payable and accrued liabilities are as follows: (in thousands) September 30, 2023 December 31, 2022 Employee accruals $ 18,177 $ 20,214 Commercial accruals 13,437 8,620 Accrued R&D projects 5,678 5,350 Trade payables 8,854 3,087 Other accrued liabilities 5,938 2,094 Income taxes payable 225 625 Total accounts payable and accrued liabilities $ 52,309 $ 39,990

Net Loss per Common Share (Tabl

Net Loss per Common Share (Tables)	9 Months Ended
	Sep. 30, 2023
Earnings Per Share [Abstract]
Schedule of Loss Per Share, Basic and Diluted	The numerator and denominator used in the calculation of basic and diluted net loss per common share are as follows: Three months ended Nine months ended (in thousands, except per share data) 2023 2022 2023 2022 Net loss $ (13,447) $ (8,989) $ (51,145) $ (82,134) Weighted average common shares outstanding 142,847 141,856 143,085 141,831 Net loss per common share (expressed in $ per share) $ (0.09) $ (0.06) $ (0.36) $ (0.58)
Schedule of Antidilutive Securities Excluded from Computation of Loss Per Share	The Company did not include the securities in the following table in the computation of the net loss per common share because the effect would have been anti-dilutive during each period: Nine months ended (in thousands) 2023 2022 Stock options 12,400 14,299 Unvested performance awards 921 — Unvested restricted stock units 6,968 2,098 20,289 16,397

Share-based Compensation (Table

Share-based Compensation (Tables)	9 Months Ended
	Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]
Schedule of Share-based Payment Award Valuation Assumptions	The following weighted average assumptions were used to estimate the fair value of the options granted during the nine months ended September 30, 2023 and September 30, 2022: 2023 2022 Annualized volatility 71 % 70 % Risk-free interest rate 3.92 % 2.01 % Expected life of options in years 5.0 years 5.0 years Estimated forfeiture rate 12.7 % 12.1 % Dividend rate 0.0 % 0.0% Fair value per common share option $ 5.94 $ 6.60
Schedule of Option Activity	The following table summarizes the option award activity for the nine months ended September 30, 2023: September 30, 2023 Number of shares (in thousands) Weighted average exercise price $ Outstanding - December 31, 2022 13,295 $ 12.09 Granted 675 9.68 Exercised (558) 5.27 Forfeited (1,012) 14.11 Outstanding - September 30, 2023 12,400 $ 12.10
Schedule of Performance Shares Activity	The following table summarizes the RSU and PA activity for the nine months ended September 30, 2023: September 30, 2023 Number of shares (in thousands) Weighted average fair value price $ Outstanding - December 31, 2022 1,980 $ 10.84 Granted 6,775 9.04 Vested (569) 11.71 Forfeited (297) 9.31 Outstanding - September 30, 2023 7,889 $ 9.29
Allocation of Share-Based Payments	The Company recognized share-based compensation expense for the three and nine months ended September 30, 2023 and September 30, 2022 as follows: Three months ended Nine months ended (in thousands) 2023 2022 2023 2022 Research and development $ 1,975 $ 1,489 $ 5,679 $ 3,531 Selling, general and administrative 9,560 6,625 26,969 21,480 Capitalized under inventories 273 206 895 387 Share-based compensation expense $ 11,808 $ 8,320 $ 33,543 $ 25,398

Organization and Description _2

Organization and Description of Business (Details)	Aug. 17, 2021 novelAsset
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of additional novel assets	2

Summary of Significant Accoun_4

Summary of Significant Accounting Policies- Narrative (Details)	9 Months Ended
	Sep. 30, 2023 USD ($) segment	Dec. 31, 2022 USD ($)
Property, Plant and Equipment [Line Items]
Number of operating segments | segment	1
Cash and cash equivalents and investments	$ 338,500,000
Number of customers | segment	2
Accounts receivable, net	$ 37,946,000	$ 13,483,000
Allowance for doubtful accounts	$ 0	$ 0
Minimum
Property, Plant and Equipment [Line Items]
Receivable standard credit terms (in days)	30 days
Maximum
Property, Plant and Equipment [Line Items]
Receivable standard credit terms (in days)	45 days

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Schedule of Total Revenues, Net From Main Customers (Details) - Two Specialty Pharmacy - Revenue Benchmark - Customer Concentration Risk	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Product revenue, net
Property, Plant and Equipment [Line Items]
Concentration risk (as percent)	77%	48%	90%	74%
License, royalty and collaboration revenue
Property, Plant and Equipment [Line Items]
Concentration risk (as percent)	21%	52%	9%	26%

Fair Value Measurements - Asset

Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Financial assets:
Total financial assets	$ 338,491	$ 389,390
Cash, cash equivalents and restricted cash
Financial assets:
Total financial assets	46,397	94,172
U.S. agency securities
Financial assets:
Total financial assets		4,948
Corporate bonds
Financial assets:
Total financial assets	32,396	104,080
Commercial paper
Financial assets:
Total financial assets	93,916	125,187
Treasury bills
Financial assets:
Total financial assets	80,213	12,282
Treasury bonds
Financial assets:
Total financial assets	85,569	42,220
Yankee bonds
Financial assets:
Total financial assets	0	6,501
Level 1
Financial assets:
Total financial assets	46,397	94,172
Level 1 | Cash, cash equivalents and restricted cash
Financial assets:
Total financial assets	46,397	94,172
Level 1 | U.S. agency securities
Financial assets:
Total financial assets		0
Level 1 | Corporate bonds
Financial assets:
Total financial assets	0	0
Level 1 | Commercial paper
Financial assets:
Total financial assets	0	0
Level 1 | Treasury bills
Financial assets:
Total financial assets	0	0
Level 1 | Treasury bonds
Financial assets:
Total financial assets	0	0
Level 1 | Yankee bonds
Financial assets:
Total financial assets	0	0
Level 2
Financial assets:
Total financial assets	$ 292,094	$ 295,218
Derivative, average remaining maturity	7 months	7 months
Level 2 | Cash, cash equivalents and restricted cash
Financial assets:
Total financial assets	$ 0	$ 0
Level 2 | U.S. agency securities
Financial assets:
Total financial assets		4,948
Level 2 | Corporate bonds
Financial assets:
Total financial assets	32,396	104,080
Level 2 | Commercial paper
Financial assets:
Total financial assets	93,916	125,187
Level 2 | Treasury bills
Financial assets:
Total financial assets	80,213	12,282
Level 2 | Treasury bonds
Financial assets:
Total financial assets	85,569	42,220
Level 2 | Yankee bonds
Financial assets:
Total financial assets	0	6,501
Level 3
Financial assets:
Total financial assets	0	0
Level 3 | Cash, cash equivalents and restricted cash
Financial assets:
Total financial assets	0	0
Level 3 | U.S. agency securities
Financial assets:
Total financial assets		0
Level 3 | Corporate bonds
Financial assets:
Total financial assets	0	0
Level 3 | Commercial paper
Financial assets:
Total financial assets	0	0
Level 3 | Treasury bills
Financial assets:
Total financial assets	0	0
Level 3 | Treasury bonds
Financial assets:
Total financial assets	0	0
Level 3 | Yankee bonds
Financial assets:
Total financial assets	$ 0	$ 0

Cash, Cash Equivalents, Restr_3

Cash, Cash Equivalents, Restricted Cash and Investments - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Investments, Debt and Equity Securities [Abstract]
Total cash, cash equivalents, restricted cash and investments	$ 338,500		$ 338,500		$ 389,400
Available-for-sale debt securities	292,100		292,100		295,200
Interest receivable	700		700		$ 1,100
Unrealized gain (loss) on available-for-sale securities	$ 73	$ 300	$ 114	$ (700)

Cash, Cash Equivalents, Restr_4

Cash, Cash Equivalents, Restricted Cash and Investments - Investments (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Marketable Securities [Line Items]
Amortized Cost	$ 338,041	$ 389,646
Unrealized Gains	3	0
Unrealized Losses	(144)	(256)
Estimated Fair Value	337,900	389,390
Total cash, cash equivalents, restricted cash and investments	338,491
Cash, cash equivalents and restricted cash
Marketable Securities [Line Items]
Amortized Cost	46,397	94,172
Unrealized Gains	0	0
Unrealized Losses	0	0
Estimated Fair Value	46,397	94,172
U.S. agency securities
Marketable Securities [Line Items]
Amortized Cost		4,951
Unrealized Gains		0
Unrealized Losses		(3)
Estimated Fair Value		4,948
Corporate bonds
Marketable Securities [Line Items]
Amortized Cost	31,820	104,174
Unrealized Gains	0	0
Unrealized Losses	(15)	(94)
Estimated Fair Value	31,805	104,080
Commercial paper
Marketable Securities [Line Items]
Amortized Cost	93,960	125,255
Unrealized Gains	0	0
Unrealized Losses	(44)	(68)
Estimated Fair Value	93,916	125,187
Treasury bills
Marketable Securities [Line Items]
Amortized Cost	80,210	12,290
Unrealized Gains	3	0
Unrealized Losses	0	(8)
Estimated Fair Value	80,213	12,282
Treasury bonds
Marketable Securities [Line Items]
Amortized Cost	85,654	42,301
Unrealized Gains	0	0
Unrealized Losses	(85)	(81)
Estimated Fair Value	85,569	42,220
Yankee bonds
Marketable Securities [Line Items]
Amortized Cost	0	6,503
Unrealized Gains	0	0
Unrealized Losses	0	(2)
Estimated Fair Value	0	$ 6,501
Long-term corporate bond
Marketable Securities [Line Items]
Amortized Cost	592
Unrealized Gains	0
Unrealized Losses	(1)
Estimated Fair Value	$ 591

Inventories, net (Details)

Inventories, net (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Inventory Disclosure [Abstract]
Finished goods inventories	$ 1,100	$ 3,900
Raw materials	1,985	2,217
Work in process	29,639	21,059
Finished goods, net of reserve	1,196	1,476
Total inventories, net	$ 32,820	$ 24,752

Prepaid Expenses (Details)

Prepaid Expenses (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid assets	$ 7,288	$ 5,451
Prepaid deposits	6,922	6,330
Prepaid insurance	1,948	1,799
Total prepaid expenses	$ 16,158	$ 13,580

Intangible Assets - Schedule of

Intangible Assets - Schedule of Intangible Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	$ 19,801	$ 19,568
Accumulated Amortization	(14,540)	(13,143)
Net Carrying Amount	5,261	6,425
Patents
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	1,802	1,569
Accumulated Amortization	(1,287)	(1,262)
Net Carrying Amount	515	307
Acquired intellectual property and reacquired rights
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	15,126	15,126
Accumulated Amortization	(10,538)	(9,838)
Net Carrying Amount	4,588	5,288
Internal-use software implementation costs
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	2,873	2,873
Accumulated Amortization	(2,715)	(2,043)
Net Carrying Amount	$ 158	$ 830

Intangible Assets - Narrative (

Intangible Assets - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization of intangible assets	$ 0.5	$ 0.5	$ 1.4	$ 1.6

Property and Equipment, net (De

Property and Equipment, net (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 5,250	$ 5,105
Less accumulated depreciation	(1,754)	(1,455)
Property and equipment, net	3,496	3,650
Construction in progress
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	0	255
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	3,243	2,978
Office equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	631	645
Furniture
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	1,141	976
Computer equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 235	$ 251

Lease Obligations - Narrative (

Lease Obligations - Narrative (Details) $ in Thousands, SFr in Millions	1 Months Ended				3 Months Ended				9 Months Ended		12 Months Ended
	Feb. 28, 2021 USD ($)	Feb. 28, 2021 CHF (SFr)	Jan. 31, 2021 CHF (SFr)	Mar. 31, 2020 ft² extension_option	Sep. 30, 2023 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2023 CHF (SFr)	Sep. 30, 2022 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Dec. 31, 2022 USD ($)	Jul. 31, 2023 USD ($)	Oct. 31, 2022 ft²	Mar. 12, 2020
Lessee, Lease, Description [Line Items]
Operating right-of-use assets, net					$ 4,609				$ 4,609		$ 4,907
Total future minimum lease payments					$ 7,693				$ 7,693
Operating lease, weighted average discount rate					5.28%				5.28%
Operating lease costs					$ 200			$ 200	$ 600	$ 800
Finance lease payment									3,482	$ 0
Finance right-of-use asset, net					113,069				113,069		0
Finance lease, liability					$ 85,521				$ 85,521
Finance lease, weighted average discount rate					6.19%				6.19%
Rockville, Maryland
Lessee, Lease, Description [Line Items]
Area of property (in sqft) | ft²				30,531
Remaining lease term				8 years
Number of extension options | extension_option				2
Lease extension term				5 years
Lease term				11 years
Lease termination option term				7 years
Operating right-of-use assets, net					$ 4,600				$ 4,600		4,900
Total future minimum lease payments					7,500				7,500		8,000
Proceeds from tenant improvements											$ 2,300
Operating lease, weighted average discount rate														5.20%
Edmonton, Alberta
Lessee, Lease, Description [Line Items]
Area of property (in sqft) | ft²													4,375
Remaining lease term													6 years
Lease extension term													5 years
Monoplant
Lessee, Lease, Description [Line Items]
Payments for capital improvements | SFr			SFr 21
Finance lease payment	$ 11,800	SFr 10.5				$ 11,900	SFr 10.5
Finance right-of-use asset, net					113,100				113,100			$ 117,600
Finance lease, liability					85,500				85,500			$ 94,100
Finance lease, weighted average discount rate												6.19%
Operating right-of-use assets, net					4,400				4,600
Interest expense					1,400				1,500
Beinheim
Lessee, Lease, Description [Line Items]
Expected payments prior to commencement of lease					1,000				1,000
Future value of minimum lease payments of leases not yet commenced					$ 100				$ 100

Lease Obligations - Summary of

Lease Obligations - Summary of Components of Leasing Costs and Rent (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Leases [Abstract]
Operating lease, weighted average remaining lease term (years)	7 years 10 months 24 days
Operating lease, weighted average discount rate	5.28%
Finance lease, operating lease, weighted average remaining lease term (years)	6 years 6 months
Finance lease, weighted average discount rate	6.19%
Cash paid for amounts included in the measurement of lease liabilities
Financing cash flows from finance lease	$ (3,482)	$ 0
Operating cash flows from finance lease	(718)	0
Operating cash flows from operating leases	$ (805)	$ (897)

Lease Obligations - Schedule of

Lease Obligations - Schedule of Maturities of Lease Liabilities (Details) $ in Thousands	Sep. 30, 2023 USD ($)
Finance Lease Payments
Remainder of 2023	$ 3,963
2024	15,851
2025	15,851
2026	15,851
2027	15,851
Thereafter	35,663
Total future minimum lease payments	103,030
Less: lease imputed interest	(17,509)
Total future minimum lease payments	85,521
Operating Lease Payments
Remainder of 2023	276
2024	1,113
2025	1,141
2026	1,169
2027	1,198
Thereafter	4,533
Total future minimum lease payments	9,430
Less: lease imputed interest	(1,737)
Total future minimum lease payments	$ 7,693

Accounts Payable and Accrued _3

Accounts Payable and Accrued Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Payables and Accruals [Abstract]
Employee accruals	$ 18,177	$ 20,214
Commercial accruals	13,437	8,620
Accrued R&D projects	5,678	5,350
Trade payables	8,854	3,087
Other accrued liabilities	5,938	2,094
Income taxes payable	225	625
Total accounts payable and accrued liabilities	$ 52,309	$ 39,990

Deferred Compensation and Oth_2

Deferred Compensation and Other Non-current Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Payables and Accruals [Abstract]
Other non-current liabilities	$ 10,340	$ 12,166

License and Collaboration Agr_2

License and Collaboration Agreements (Details) - USD ($) $ in Thousands		3 Months Ended			9 Months Ended		12 Months Ended
	Aug. 17, 2021	Sep. 30, 2023	Sep. 30, 2022	Mar. 31, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2020	Sep. 15, 2022
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenues		$ 54,515	$ 55,779		$ 130,418	$ 105,595
Research and development		13,605	10,973		39,413	35,118
Otuska | License Agreement Terms
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Upfront payments received							$ 50,000
Potential regulatory milestone revenue							$ 50,000
Triggered milestone, payments								$ 30,000
Revenues		10,000
Otuska | License Agreement Terms | Service Revenue
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenues		$ 12,700	$ 30,200		$ 13,200	$ 30,400
Otuska | License Agreement Terms | Minimum
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Tiered royalty percentages on future sales							10%
Otuska | License Agreement Terms | Maximum
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Tiered royalty percentages on future sales							20%
Riptide Bioscience, Inc. | License Agreement Terms
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Upfront license fee	$ 6,000
Research and development				$ 4,000

Net Loss per Common Share - Sch

Net Loss per Common Share - Schedule of Earnings Per Share, Basic and Diluted (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Earnings Per Share [Abstract]
Net loss	$ (13,447)	$ (8,989)	$ (51,145)	$ (82,134)
Weighted average common shares outstanding basic (in shares)	142,847,000	141,856,000	143,085,000	141,831,000
Weighted average common shares outstanding diluted (in shares)	142,847,000	141,856,000	143,085,000	141,831,000
Basic Net loss per common share (expressed in usd per share))	$ (0.09)	$ (0.06)	$ (0.36)	$ (0.58)
Diluted Net loss per common share (expressed in usd per share)	$ (0.09)	$ (0.06)	$ (0.36)	$ (0.58)

Net Loss per Common Share - Ant

Net Loss per Common Share - Anti-Dilutive Securities (Details) - shares shares in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	20,289	16,397
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	12,400	14,299
Unvested performance awards
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	921	0
Unvested restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	6,968	2,098

Share-based Compensation - Narr

Share-based Compensation - Narrative (Details) $ in Millions	1 Months Ended	3 Months Ended		9 Months Ended
	Jun. 30, 2021 shares	Mar. 31, 2023 purchase_period	Mar. 31, 2022 purchase_period	Sep. 30, 2023 USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized share-based compensation expense | $				$ 39.2
Unrecognized share-based compensation expense weighted average recognition period (in years)				1 year 4 months 24 days
Employee Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized	2,500,000
Number of purchase periods | purchase_period		2	4
Purchase period		12 months	24 months
Offering period		12 months
Amended and Restated Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of additional shares authorized	23,800,000

Share-based Compensation - Weig

Share-based Compensation - Weighted Average Assumptions (Details) - USD ($)	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]
Annualized volatility (as percent)	71%	70%
Risk-free interest rate (as percent)	3.92%	2.01%
Expected life of options in years	5 years	5 years
Estimated forfeiture rate (as percent)	12.70%	12.10%
Dividend rate	$ 0	$ 0
Fair value per common share option (in usd per share)	$ 5.94	$ 6.60

Share-based Compensation - Stoc

Share-based Compensation - Stock Option Activity (Details) shares in Thousands	9 Months Ended
	Sep. 30, 2023 $ / shares shares	Dec. 31, 2022 $ / shares
Number of shares (in thousands)
Beginning balance (in shares) | shares	13,295
Granted (in shares) | shares	675
Exercised (in shares) | shares	(558)
Forfeited (in shares) | shares	(1,012)
Ending balance (in shares) | shares	12,400
Weighted average exercise price $
Beginning balance (in usd per share) | $ / shares	$ 12.10	$ 12.09
Granted (in usd per share) | $ / shares	9.68
Exercised (in usd per share) | $ / shares	5.27
Forfeited (in usd per share) | $ / shares	14.11
Ending balance (in usd per share) | $ / shares	$ 12.10

Share-based Compensation - Perf

Share-based Compensation - Performance Awards and Restricted Stock Units Activity (Details) - Officer - Performance Share sand Restricted Stock Units (RSUs) shares in Thousands	9 Months Ended
	Sep. 30, 2023 $ / shares shares
Number of shares (in thousands)
Outstanding - Beginning of Period (in shares) | shares	1,980
Granted (in shares) | shares	6,775
Vested (in shares) | shares	(569)
Forfeited (in shares) | shares	(297)
Outstanding - End of Period (in shares) | shares	7,889
Weighted average exercise price $
Outstanding, Weighted average exercise price - Beginning of Period (in usd per share) | $ / shares	$ 10.84
Weighted average grant date fair value (in usd per share) | $ / shares	9.04
Weighted average grant date fair value (in usd per share) | $ / shares	11.71
Weighted average exercise price (in usd per share) | $ / shares	9.31
Outstanding, Weighted average exercise price - End of Period (in usd per share) | $ / shares	$ 9.29

Share-based Compensation - Allo

Share-based Compensation - Allocated Share-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	$ 11,808	$ 8,320	$ 33,543	$ 25,398
Research and development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	1,975	1,489	5,679	3,531
Selling, general and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	9,560	6,625	26,969	21,480
Capitalized under inventories
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	$ 273	$ 206	$ 895	$ 387

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Income Tax Disclosure [Abstract]
Income tax (benefit) expense	$ 298	$ 954	$ 92	$ 973

Related-Party Transactions (Det

Related-Party Transactions (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Related Party Transaction [Line Items]
Other current liabilities	$ 2,611	$ 2,033
Other non-current liabilities	$ 10,340	$ 12,166
Milestone Achieved | Related Party | ILJIN
Related Party Transaction [Line Items]
Ownership percentage	5%
Milestone Achieved | ILJIN
Related Party Transaction [Line Items]
Other current liabilities	$ 500
Employee Benefit Obligations | Dr. Robert T. Foster
Related Party Transaction [Line Items]
Other current liabilities	500
Other non-current liabilities	$ 6,400